1278 related articles for article (PubMed ID: 21775338)
1. Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09.
Davies TA; Marie Queenan A; Morrow BJ; Shang W; Amsler K; He W; Lynch AS; Pillar C; Flamm RK
J Antimicrob Chemother; 2011 Oct; 66(10):2298-307. PubMed ID: 21775338
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
[TBL] [Abstract][Full Text] [Related]
3. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
Mushtaq S; Vickers A; Woodford N; Livermore DM
J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
[TBL] [Abstract][Full Text] [Related]
4. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status.
Esterly JS; Qi C; Malczynski M; Scheetz MH
Pharmacotherapy; 2010 Apr; 30(4):354-60. PubMed ID: 20334455
[TBL] [Abstract][Full Text] [Related]
5. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
[TBL] [Abstract][Full Text] [Related]
6. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
[TBL] [Abstract][Full Text] [Related]
7. Activities of doripenem against nosocomial bacteremic drug-resistant Gram-negative bacteria in a medical center in Taiwan.
Dong SX; Wang JT; Chang SC
J Microbiol Immunol Infect; 2012 Dec; 45(6):459-64. PubMed ID: 23102796
[TBL] [Abstract][Full Text] [Related]
8. Comparative Activity of Carbapenem Testing (COMPACT) study in Germany.
Valenza G; Seifert H; Decker-Burgard S; Laeuffer J; Morrissey I; Mutters R;
Int J Antimicrob Agents; 2012 Mar; 39(3):255-8. PubMed ID: 22230334
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
[TBL] [Abstract][Full Text] [Related]
10. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
El Amin N; Giske CG; Jalal S; Keijser B; Kronvall G; Wretlind B
APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
[TBL] [Abstract][Full Text] [Related]
11. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenem-resistant Pseudomonas aeruginosa isolates from South Korea.
Lee JY; Ko KS
Int J Antimicrob Agents; 2012 Aug; 40(2):168-72. PubMed ID: 22633564
[TBL] [Abstract][Full Text] [Related]
12. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration.
Landman D; Babu E; Shah N; Kelly P; Olawole O; Bäcker M; Bratu S; Quale J
J Antimicrob Chemother; 2012 Jun; 67(6):1427-31. PubMed ID: 22378678
[TBL] [Abstract][Full Text] [Related]
13. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
[TBL] [Abstract][Full Text] [Related]
14. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.
Livermore DM; Warner M; Mushtaq S
J Antimicrob Chemother; 2013 Oct; 68(10):2286-90. PubMed ID: 23696619
[TBL] [Abstract][Full Text] [Related]
15. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931
[TBL] [Abstract][Full Text] [Related]
16. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
17. First Detection of VIM-4-Producing Pseudomonas aeruginosa and OXA-48-Producing Klebsiella pneumoniae in Northeastern (Annaba, Skikda) Algeria.
Mellouk FZ; Bakour S; Meradji S; Al-Bayssari C; Bentakouk MC; Zouyed F; Djahoudi A; Boutefnouchet N; Rolain JM
Microb Drug Resist; 2017 Apr; 23(3):335-344. PubMed ID: 27314660
[TBL] [Abstract][Full Text] [Related]
18. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
19. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]